Final overall survival results from the Phase 3 ROSELLA study show relacorilant plus nab-paclitaxel reduced the risk of death versus nab-paclitaxel alone in platinum-resistant ovarian cancer. The update was presented at the 2026 SGO Annual Meeting and followed regulatory use in clinical guidance. Across 188 patients receiving relacorilant plus nab-paclitaxel versus 193 on nab-paclitaxel monotherapy, median OS was 16.0 months versus 11.9 months (hazard ratio 0.65; P=0.0004). The benefit held across prespecified subgroups, including varying prior PARP exposure and platinum-free interval length. The article also notes the FDA approval of the relacorilant combination in March 2026 and placement as a preferred option in NCCN guidelines for platinum-resistant ovarian cancer. The final OS data further strengthens the regimen’s positioning in a hard-to-treat setting.